Frontiers in Oncology (Jun 2021)
Single-Cell RNA-seq Identification of the Cellular Molecular Characteristics of Sporadic Bilateral Clear Cell Renal Cell Carcinoma
- Zhenyuan Yu,
- Zhenyuan Yu,
- Zhenyuan Yu,
- Zhenyuan Yu,
- Zhenyuan Yu,
- Wenhao Lu,
- Wenhao Lu,
- Wenhao Lu,
- Wenhao Lu,
- Wenhao Lu,
- Cheng Su,
- Cheng Su,
- Cheng Su,
- Cheng Su,
- Yufang Lv,
- Yufang Lv,
- Yufang Lv,
- Yufang Lv,
- Yufang Lv,
- Yu Ye,
- Yu Ye,
- Yu Ye,
- Yu Ye,
- Yu Ye,
- Bingqian Guo,
- Bingqian Guo,
- Bingqian Guo,
- Deyun Liu,
- Deyun Liu,
- Haibiao Yan,
- Haibiao Yan,
- Hua Mi,
- Hua Mi,
- Tianyu Li,
- Tianyu Li,
- Qingyun Zhang,
- Qingyun Zhang,
- Qingyun Zhang,
- Qingyun Zhang,
- Qingyun Zhang,
- Jiwen Cheng,
- Jiwen Cheng,
- Jiwen Cheng,
- Jiwen Cheng,
- Jiwen Cheng,
- Zengnan Mo,
- Zengnan Mo,
- Zengnan Mo,
- Zengnan Mo,
- Zengnan Mo
Affiliations
- Zhenyuan Yu
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zhenyuan Yu
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zhenyuan Yu
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zhenyuan Yu
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zhenyuan Yu
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Wenhao Lu
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Wenhao Lu
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Wenhao Lu
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Wenhao Lu
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Wenhao Lu
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Cheng Su
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Cheng Su
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Cheng Su
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Cheng Su
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Yufang Lv
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Yufang Lv
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yufang Lv
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Yufang Lv
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yufang Lv
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Yu Ye
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yu Ye
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Yu Ye
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Yu Ye
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Yu Ye
- Scientific Research Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
- Bingqian Guo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Bingqian Guo
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Bingqian Guo
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Deyun Liu
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Deyun Liu
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Haibiao Yan
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Haibiao Yan
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Hua Mi
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Hua Mi
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Tianyu Li
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Tianyu Li
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Qingyun Zhang
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Qingyun Zhang
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Qingyun Zhang
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Qingyun Zhang
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Qingyun Zhang
- Department of Urology, Affiliated Tumour Hospital of Guangxi Medical University, Nanning, China
- Jiwen Cheng
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Jiwen Cheng
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Jiwen Cheng
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Jiwen Cheng
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Jiwen Cheng
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- Zengnan Mo
- Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zengnan Mo
- Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zengnan Mo
- Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
- Zengnan Mo
- Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China
- Zengnan Mo
- Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Key Laboratory of Colleges and Universities, Nanning, China
- DOI
- https://doi.org/10.3389/fonc.2021.659251
- Journal volume & issue
-
Vol. 11
Abstract
Bilateral renal cell carcinoma (RCC) is a rare disease that can be classified as either familial or sporadic. Studying the cellular molecular characteristics of sporadic bilateral RCC is important to provide guidance for clinical treatment. Cellular molecular characteristics can be expressed at the RNA level, especially at the single-cell degree. Single-cell RNA sequencing (scRNA-seq) was performed on bilateral clear cell RCC (ccRCC). A total of 3,575 and 3,568 high-quality single-cell transcriptome data were captured from the left and right tumour tissues, respectively. Gene characteristics were identified by comparing left and right tumours at the scRNA level. The complex cellular environment of bilateral ccRCC was presented by using scRNA-seq. Single-cell transcriptomic analysis revealed high similarity in gene expression among most of the cell types of bilateral RCCs but significant differences in gene expression among different site tumour cells. Additionally, the potential biological function of different tumour cell types was determined by gene ontology (GO) analysis. The transcriptome characteristics of tumour tissues in different locations at the single-cell transcriptome level were revealed through the scRNA-seq of bilateral sporadic ccRCC. This work provides new insights into the diagnosis and treatment of bilateral RCC.
Keywords
- single-cell RNA sequencing
- sporadic bilateral clear cell renal cell carcinoma
- tumour cellular molecular characteristics
- single-cell RNA atlas
- tumour cell microenvironment
